DK1140203T3 - Farmaceutiske præparater som vitronectinreceptorantagonist - Google Patents

Farmaceutiske præparater som vitronectinreceptorantagonist

Info

Publication number
DK1140203T3
DK1140203T3 DK99967442T DK99967442T DK1140203T3 DK 1140203 T3 DK1140203 T3 DK 1140203T3 DK 99967442 T DK99967442 T DK 99967442T DK 99967442 T DK99967442 T DK 99967442T DK 1140203 T3 DK1140203 T3 DK 1140203T3
Authority
DK
Denmark
Prior art keywords
novel compounds
present
contrast agent
treatment
provides novel
Prior art date
Application number
DK99967442T
Other languages
Danish (da)
English (en)
Inventor
Milind Rajopadhye
Thomas David Harris
Edward H Cheesman
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Application granted granted Critical
Publication of DK1140203T3 publication Critical patent/DK1140203T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0002General or multifunctional contrast agents, e.g. chelated agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N25/00Investigating or analyzing materials by the use of thermal means
    • G01N25/20Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity
    • G01N25/48Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation
    • G01N25/4806Details not adapted to a particular type of sample
    • G01N25/4813Details not adapted to a particular type of sample concerning the measuring means
    • G01N25/482Details not adapted to a particular type of sample concerning the measuring means concerning the temperature responsive elements
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N25/00Investigating or analyzing materials by the use of thermal means
    • G01N25/20Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity
    • G01N25/48Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation
    • G01N25/4846Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample
    • G01N25/4866Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample by using a differential method
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00279Features relating to reactor vessels
    • B01J2219/00306Reactor vessels in a multiple arrangement
    • B01J2219/00313Reactor vessels in a multiple arrangement the reactor vessels being formed by arrays of wells in blocks
    • B01J2219/00315Microtiter plates
    • B01J2219/00317Microwell devices, i.e. having large numbers of wells
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00495Means for heating or cooling the reaction vessels
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00659Two-dimensional arrays
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/0068Means for controlling the apparatus of the process
    • B01J2219/00702Processes involving means for analysing and characterising the products
    • B01J2219/00707Processes involving means for analysing and characterising the products separated from the reactor apparatus
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B60/00Apparatus specially adapted for use in combinatorial chemistry or with libraries
    • C40B60/14Apparatus specially adapted for use in combinatorial chemistry or with libraries for creating libraries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Combustion & Propulsion (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK99967442T 1998-12-18 1999-12-17 Farmaceutiske præparater som vitronectinreceptorantagonist DK1140203T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11282998P 1998-12-18 1998-12-18
PCT/US1999/030312 WO2000035488A2 (fr) 1998-12-18 1999-12-17 Medicaments antagonistes du recepteur de la vitronectine

Publications (1)

Publication Number Publication Date
DK1140203T3 true DK1140203T3 (da) 2007-09-10

Family

ID=22346047

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99967442T DK1140203T3 (da) 1998-12-18 1999-12-17 Farmaceutiske præparater som vitronectinreceptorantagonist

Country Status (10)

Country Link
EP (1) EP1140203B1 (fr)
AT (1) ATE362772T1 (fr)
AU (1) AU2371500A (fr)
CA (1) CA2346935A1 (fr)
DE (1) DE69936148T2 (fr)
DK (1) DK1140203T3 (fr)
ES (1) ES2288040T3 (fr)
PT (1) PT1140203E (fr)
TR (1) TR200101775T2 (fr)
WO (1) WO2000035488A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
EP1296678A2 (fr) * 2000-06-21 2003-04-02 Bristol-Myers Squibb Pharma Company Produits pharmaceutiques d'antagonistes recepteurs de la vitronectine utilises en polytherapie
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
WO2003062198A1 (fr) 2002-01-24 2003-07-31 Barnes Jewish Hospital Agents d'imagerie ciblant des integrines
US7279150B2 (en) 2002-01-24 2007-10-09 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
GB0305422D0 (en) * 2003-03-10 2003-04-16 Univ Open Detection, monitoring and treatment of cancer
EP1622647B1 (fr) * 2003-05-12 2009-11-25 Lantheus Medical Imaging, Inc. Composes de l antagoniste du recepteur de la vitronectine et leur utilisation dans la preparation de produits radio pharmaceutiques
US7319149B2 (en) * 2003-06-13 2008-01-15 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
EP1768558A4 (fr) 2004-06-09 2009-11-25 Kereos Inc Derives lipophiles de monoamides chelates
WO2006004429A2 (fr) * 2004-07-02 2006-01-12 Ge Healthcare As Agents d'imagerie avec profils pharmacocinetiques ameliores
JP6215335B2 (ja) * 2013-09-24 2017-10-18 富士フイルム株式会社 新規な含窒素化合物もしくはその塩またはそれらと金属との錯体
JP6286467B2 (ja) * 2015-03-25 2018-02-28 富士フイルム株式会社 インテグリンが関与する疾患の診断または治療の処置剤
MX2017012184A (es) * 2015-03-25 2018-01-09 Fujifilm Corp Metodo para manufacturar compuesto novedoso que contiene nitrogeno o sal del mismo e intermediario de manufacturacion del compuesto novedoso que contiene nitrogeno o sal del mismo.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10504807A (ja) * 1994-06-29 1998-05-12 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗剤
GB9511989D0 (en) * 1995-06-13 1995-08-09 Glaxo Group Ltd Chemical compounds
RO118289B1 (ro) * 1995-08-30 2003-04-30 Gd Searle & Co Chicago Derivati de fenilcarboniluree si compozitie farmaceutica
AU1345697A (en) * 1995-12-22 1997-07-17 Du Pont Merck Pharmaceutical Company, The Novel integrin receptor antagonists
ZA978758B (en) * 1996-10-02 1999-03-30 Du Pont Merck Pharma Technetium-99m-labeled chelator incorporated cyclic peptides that bind to the GPIIb/IIIa receptor as imaging agents
AU4753997A (en) * 1996-10-16 1998-05-11 Burnham Institute, The Magnetic resonance imaging of thrombi
AU8689798A (en) * 1997-08-04 1999-02-22 Smithkline Beecham Corporation Integrin receptor antagonists
WO2000006169A1 (fr) * 1998-07-29 2000-02-10 Merck & Co., Inc. Antagonistes des recepteurs de l'integrine

Also Published As

Publication number Publication date
AU2371500A (en) 2000-07-03
WO2000035488A3 (fr) 2000-11-09
DE69936148D1 (de) 2007-07-05
WO2000035488A2 (fr) 2000-06-22
EP1140203A2 (fr) 2001-10-10
ES2288040T3 (es) 2007-12-16
CA2346935A1 (fr) 2000-06-22
PT1140203E (pt) 2007-08-30
EP1140203B1 (fr) 2007-05-23
ATE362772T1 (de) 2007-06-15
DE69936148T2 (de) 2008-01-24
TR200101775T2 (tr) 2002-07-22

Similar Documents

Publication Publication Date Title
WO2000035492A3 (fr) Medicaments antagonistes du recepteur de la vitronectine
WO1999058162A3 (fr) Produits pharmaceutiques pour l'imagerie de troubles angiogenes
WO2000035887A3 (fr) Medicaments antagonistes du recepteur de la vitronectine
DK1140203T3 (da) Farmaceutiske præparater som vitronectinreceptorantagonist
WO2001098294A3 (fr) Produits pharmaceutiques d'antagonistes recepteurs de la vitronectine utilises en polytherapie
WO2001097861A3 (fr) Agents pharmaceutiques antagonistes du recepteur de la vitronectine destines a etre utilises dans une therapie combinee
O'Connell et al. Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET
WO2001097860A3 (fr) Produits pharmaceutiques pour l'imagerie de troubles angiogeniques
NO20031323D0 (no) Peptid-baserte forbindelser
Nedrow et al. Targeting PSMA with a Cu-64 labeled phosphoramidate inhibitor for PET/CT imaging of variant PSMA-expressing xenografts in mouse models of prostate cancer
Pandey et al. Comparative positron-emission tomography (PET) imaging and phototherapeutic potential of 124I-labeled methyl-3-(1′-iodobenzyloxyethyl) pyropheophorbide-a vs the corresponding glucose and galactose conjugates
DE60136632D1 (de) Vitronectin rezeptor antagonist pharmaka
Carpenter et al. Halogenated Benzimidazole Carboxamides Target Integrin α4β1 on T-Cell and B-Cell Lymphomas
ES2114570T3 (es) Utilizacion de derivados de prostaciclina para la inhibicion o el tratamiento de trastornos de la microcirculacion en el caso de la toma de agentes de contraste por rayos x, resonancia magnetica nuclear o ultrasonidos.
JP2019043892A (ja) オリゴペプチド誘導体およびそれを用いた医薬
DK0759785T3 (da) Liposomsuspensioner som blodkontrastmidler
DE60033697D1 (de) Radiomarkierte vip-analoge zur diagnose und therapie
AR023069A1 (es) Productos farmaceuticos antagonistas del receptor de vitronectina
Wang et al. Synthesis and evaluation of a radioiodinated benzothiazole derivative as a radioligand for in vivo quantitation of β‐amyloid deposits in aging and alzheimer's disease
Lekakis et al. Doxorubicin cardiotoxicity detected by indium 111 myosin-specific imaging
Roivainen et al. In Vivo Imaging of Inflammation
KR20230022470A (ko) 방사성 동위원소가 표지된 바이오틴 유도체 화합물 및 이를 유효성분으로 포함하는 암 진단용 조성물
Molea et al. Biodistribution pharmacokinetics and dosimetry of 99m Tc-D-glucaric acid in humans
Dopamine PET and Pediatric Hodgkin’s Relapse
Meredith et al. Radioimmunotherapy for metastatic prostate cancer using a high affinity antibody